Ignite Creation Date:
2025-12-25 @ 2:34 AM
Ignite Modification Date:
2026-07-02 @ 5:26 AM
Study NCT ID:
NCT06201234
Status:
RECRUITING
Last Update Posted:
2025-12-01
First Post:
2023-12-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer
Sponsor:
GBG Forschungs GmbH
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
ELEMENT GBG-114
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |